New diabetes combo shows promise in japanese study
NCT ID NCT02354235
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested whether adding canagliflozin to the existing diabetes drug teneligliptin helps Japanese adults with type 2 diabetes who still have high blood sugar. Over 24 weeks, researchers measured changes in HbA1c (a key blood sugar marker), fasting glucose, and body weight. The trial involved 138 participants and was completed to check both effectiveness and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
canagliflozin (a diabetes drug that helps lower blood sugar by making the kidneys remove sugar through urine)
What this could lead to
If successful, this could offer a new combination treatment option for people with type 2 diabetes who need better blood sugar control.
What could go wrong
This is a completed Phase 3 trial in a specific population (Japanese patients), so results may not apply to other groups. The study is relatively small (138 participants) and does not test long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Reserch site
Kanto, Japan
-
Reserch site
Kinki, Japan
-
Reserch site
Tōhoku, Japan